Press Release: ESCMID: Sanofi’s Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study
ESCMID: Sanofi's Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head…
CES 2026 Audit Shows Four Percent Growth in Participation as Innovators Showed Up in Las Vegas
Media, Policymaker, and Investor Participation Grows as Interest Surges in AI, Robotics,…
Encaleret Showed Parathyroid Hormone-Independent Normalization of Blood and Urine Calcium in Phase 2 Proof-of-Concept Study in Post-Surgical Hypoparathyroidism
September 06, 2025 14:30 ET | Source: BridgeBio Pharma, Inc. - 80%…
